Dr. Angelika Vlachou

Partner

Dr. Angelika Vlachou

Partner

Dr. Angelika Vlachou has been investing venture capital in biotech, pharma and life science start-ups for over 10 years. Over the course of her career, she has managed many transactions ranging from seed-stage venture capital and growth financing to licensing agreements, trade sale transactions and IPOs. Her expertise is also based on her virology-molecular biology research experience. One of her strengths is to combine scientific innovation with commercial potential. She is a valued sparring partner for founders, investors and stakeholders. With a doctorate in biology, she started her professional career in investment banking.

Portfolio

Posts & mentions

Blog
Blog
18. January 2024

2024: Trends, opportunities and challenges for founders

What trends and technologies can we expect to see in 2024? And what are the opportunities and challenges that founders will face? Our Partners Dr. Angelika Vlachou, Dr. Markus Kückelhaus and Markus Kreßmann provide an outlook, focusing on our investment fields industrial tech, life sciences & chemistry, and digital tech. Industrial Tech, Deep Tech and Climate Tech: An outlook by Dr. Markus Kückelhaus In the traditional industrial tech cluster, which encompasses fields such a
 
Press
15. September 2023

Successful exit for HTGF: adivo joins Zoetis to bring the benefits of species-specific antibody therapies to pet owners worldwide

adivo’s team and platform will strengthen Zoetis’ capabilities in therapeutic antibody drug discovery for companion animals. High-Tech Gründerfonds (HTGF) was among the first investors in a seed round in 2018 together with OCCIDENT and MorphoSys AG and closely supported the successful development of adivo. Dr. Kathrin Ladetzki-Baehs, Founder and CEO of adivo: “I look forward to seeing what our team can achieve as part of a leading organization with global reach while continuing
 
Press
23. May 2023

smartbax Announces Seed Financing of €1.2 Million to Develop Next-generation Antibiotics

Munich, Germany, May 23, 2023 – smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the close of its seed financing round of €1.2 million from Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF), bringing smartbax’s total capital raised to €1.9 million. The funds will be used to advance smartbax’s small molecule antibiotics through preclinical studies, expand the company’s scientific tea
 
Press
29. September 2022

Dr. Angelika Vlachou and Stefanie Grüter appointed partners at High-Tech Gründerfonds

Dr. Angelika Vlachou and Stefanie Grüter to become partners at High-Tech Gründerfonds effective 1 October 2022Dr. Angelika Vlachou to further expand her duties within the Life Sciences unit at HTGF’s Berlin office in her new role as partnerStefanie Grüter to assume responsibility for marketing, communications and relationship management in her new position Bonn/Berlin, 29 September 2022 – High-Tech Gründerfonds, leading seed investor in Germany, has appointed Stefanie Grüter
 
Press
KUPANDO Logo
26. September 2022

Kupando raises €13 million in Series A funding round

Financing led by Remiges Ventures, co-led by LifeCare Partners, with additional investments by Brandenburg Kapital, High-Tech Gründerfonds, Ventura Biomed Investors and undisclosed family offices.Proceeds to be used to complete IND-enabling work and initiate clinical development. Schönefeld/Berlin, 26. September 2022 – Kupando, a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases, anno
 
Press
7. September 2022

faCellitate, a BASF spin-off, closes a €3.7m seed round led by SARSTEDT and HTGF

Proprietary intelligent polymer surface coating platform enables development of first-in-class lab materials for modern cell culture applications Closing of seed round completed raising €3.7 million from SARSTEDT, High-Tech Gründerfonds (HTGF), R3 Consulting, ARVE Capital, ROI Verwaltungsgesellschaft and Chemovator.faCellitate has developed an intelligent and ultra-low attachment polymer surface coating platform. The first launched product thereof is targeting 3D cell culture, enabling
 

Events

Event
3. June 2024
Rooftop Pitch Potsdam
Rooftop Pitch 2024 – For Startups: Call for Application Are you lacking the right financial support? Apply now for the Rooftop Pitch Potsdam on June 3. The Potsdam Pitch Event is aimed at startups with innovative concepts. As a participant, you will have the opportunity to present your start-up concept to investors for early-stage financing. Apply now and take advantage of the opportunity to get in touch with VCs, experienced business angels, family offices and other investors.